Cell Medica, a leader in developing cellular immunotherapy for the treatment of cancer, today announced the U.S. Food and Drug Administration has granted Fast Track designation to its lead oncology product CMD-003 for patients with relapsed/refractory lymphoma and post-transplant lymphoproliferative disease associated with the oncogenic Epstein Barr virus . CMD-003, also known as baltaleucel-T, is an investigational therapy in which the patient’s T cells are activated to kill malignant cells expressing EBV antigens.